Relapsing Remitting Multiple Sclerosis Rrms Clinical Trials

ReadTheTrial indexes 3 studies for Relapsing Remitting Multiple Sclerosis Rrms. The most common development stage is Phase 3 (1 trials). Each trial page translates ClinicalTrials.gov eligibility, outcomes, and design into patient-friendly language so you can compare options quickly.

3 clinical trials found for Relapsing Remitting Multiple Sclerosis Rrms.

Pipeline by Phase

PhaseTrialsDistribution
Phase 3 1
33%
Phase 4 1
33%
N/A 1
33%

Trial Status Breakdown

Trials for Relapsing Remitting Multiple Sclerosis Rrms

A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis

NCT06700343 · RECRUITING · Phase 3

Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS)

NCT06733922 · RECRUITING · Phase 4

The Prevalence of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis: A Prospective Cross-Sectional Observational Study

NCT07497126 · ACTIVE NOT RECRUITING · N/A

Frequently Asked Questions

What clinical trials are available for Relapsing Remitting Multiple Sclerosis Rrms?

There are 3 clinical trials listed for Relapsing Remitting Multiple Sclerosis Rrms. These span various phases from early safety studies to post-approval monitoring. Browse the trial listings below for details.

How do I find recruiting Relapsing Remitting Multiple Sclerosis Rrms trials?

Look for trials with "Recruiting" status in the listings below, or visit our recruiting page to filter by condition. Each trial page includes decoded eligibility criteria to help you determine if you qualify.

What phases are Relapsing Remitting Multiple Sclerosis Rrms trials in?

Current Relapsing Remitting Multiple Sclerosis Rrms trials are distributed across: Phase 3 (1), Phase 4 (1), N/A (1).

Find More Trials